Elias Oziolor
Overview
Explore the profile of Elias Oziolor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sheehan M, Kumpf S, Qian J, Rubitski D, Oziolor E, Lanz T
Mol Ther Methods Clin Dev
. 2024 Nov;
32(4):101352.
PMID: 39506980
Evaluation of host integration profiles by adeno-associated virus (AAV) is an important component of de-risking novel AAV gene therapies. Targeted enrichment sequencing (TES) is a cost-effective and comprehensive method for...
2.
Beattie K, Verma M, Brennan R, Clausznitzer D, Damian V, Leishman D, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Oct;
13(12):2036-2051.
PMID: 39412216
Quantitative systems toxicology (QST) models are increasingly being applied for predicting and understanding toxicity liabilities in pharmaceutical research and development. A European Federation of Pharmaceutical Industries and Associations (EFPIA)-wide survey...
3.
Carratt S, Zuch de Zafra C, Oziolor E, Rana P, Vansell N, Mangipudy R, et al.
Toxicol Sci
. 2024 Sep;
203(1):28-34.
PMID: 39298459
Pharmaceutical developers are encouraged to adopt the best practices of being purposefully thoughtful about the use of animals, seeking alternatives wherever possible. They should engage with health authorities to increase...
4.
Li W, Crouse K, Alley J, Frisbie R, Fish S, Andreyeva T, et al.
J Pharmacol Exp Ther
. 2023 May;
386(1):80-92.
PMID: 37142443
Blocking chemokine receptor C-C chemoattractant cytokine (chemokine) receptor (CCR) 6-dependent T cell migration has therapeutic promise in inflammatory diseases. PF-07054894 is a novel CCR6 antagonist that blocked only CCR6, CCR7,...
5.
Oziolor E, Arat S, Martin M
BMC Bioinformatics
. 2021 Oct;
22(1):499.
PMID: 34654362
Background: Comparisons of the molecular framework among organisms can be done on both structural and functional levels. One of the most common top-down approaches for functional comparisons is RNA sequencing....
6.
Llewellyn H, Arat S, Gao J, Wen J, Xia S, Kalabat D, et al.
J Hepatol
. 2021 Jul;
75(5):1083-1095.
PMID: 34242700
Background & Aims: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs) which are more severe when ICIs are used in combination. We aimed to use a mouse...
7.
Fairbrother A, Muir D, Solomon K, Ankley G, Rudd M, Boxall A, et al.
Environ Toxicol Chem
. 2019 Jul;
38(8):1606-1624.
PMID: 31361364
Anticipating, identifying, and prioritizing strategic needs represent essential activities by research organizations. Decided benefits emerge when these pursuits engage globally important environment and health goals, including the United Nations Sustainable...
8.
Cahill C, Zhu W, Oziolor E, Yang Y, Tam B, Rajanala S, et al.
PLoS One
. 2016 Jan;
11(1):e0145184.
PMID: 26799482
The innate immune response is characterized by activation of transcription factors, nuclear factor kappa B and activator protein-1 and their downstream targets, the pro-inflammatory cytokines including interleukin 1β and interleukin...